| flecainide vs digoxin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death or hospitalization for cardiac causes | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Atrial fibrillation recurrence | 0.46 [0.08 2.83] | p=1.00 | 0 | 30 | 1 | Steinbeck (flecainide vs digoxin), | | Cardiac nonarrhythmic death | no data | | Cardiac arrhythmic death | no data | | Vascular noncardiac death | no data | | hospitalization for AF | no data | | hospitalisation for heart failure | no data | | Pro-arrhythmia | 1.00 [0.06 17.62] | p=1.00 | 0 | 30 | 1 | Steinbeck (flecainide vs digoxin), | | All cause death | 1.00 [0.02 53.89] | p=1.00 | 0 | 30 | 1 | Steinbeck (flecainide vs digoxin), | | non cardiovascular death | no data | | Adverse events leading to treatment discontinuation | 1.00 [0.02 53.89] | p=1.00 | 0 | 30 | 1 | Steinbeck (flecainide vs digoxin), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| flecainide vs no treatment | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death or hospitalization for cardiac causes | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Atrial fibrillation recurrence | 0.81 [0.32 2.08] | p=1.00 | 0 | 73 | 1 | Van Gelder, | | Cardiac nonarrhythmic death | no data | | Cardiac arrhythmic death | no data | | Vascular noncardiac death | no data | | hospitalization for AF | no data | | hospitalisation for heart failure | no data | | Pro-arrhythmia | 11.31 [0.60 212.74] | p=1.00 | 0 | 73 | 1 | Van Gelder, | | All cause death | 1.03 [0.02 53.23] | p=1.00 | 0 | 73 | 1 | Van Gelder, | | non cardiovascular death | no data | | Adverse events leading to treatment discontinuation | 15.42 [0.84 281.42] | p=1.00 | 0 | 73 | 1 | Van Gelder, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| flecainide vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death or hospitalization for cardiac causes | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Atrial fibrillation recurrence | 0.41 [0.11 1.49] | p=1.00 | 0 | 46 | 1 | Carunchio (flecainide vs placebo), | | Cardiac nonarrhythmic death | no data | | Cardiac arrhythmic death | no data | | Vascular noncardiac death | no data | | hospitalization for AF | no data | | hospitalisation for heart failure | no data | | Pro-arrhythmia | 9.10 [0.44 187.83] | p=1.00 | 0 | 46 | 1 | Carunchio (flecainide vs placebo), | | All cause death | 1.30 [0.02 68.47] | p=1.00 | 0 | 46 | 1 | Carunchio (flecainide vs placebo), | | non cardiovascular death | no data | | Adverse events leading to treatment discontinuation | 1.30 [0.02 68.47] | p=1.00 | 0 | 46 | 1 | Carunchio (flecainide vs placebo), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| flecainide vs propafenone | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death or hospitalization for cardiac causes | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Atrial fibrillation recurrence | 0.75 [0.33 1.67] | p=1.00 | 0 | 97 | 1 | Aliot, | | Cardiac nonarrhythmic death | no data | | Cardiac arrhythmic death | no data | | Vascular noncardiac death | no data | | hospitalization for AF | no data | | hospitalisation for heart failure | no data | | Pro-arrhythmia | 0.11 [0.01 2.17] | p=1.00 | 0 | 97 | 1 | Aliot, | | All cause death | 0.34 [0.01 8.57] | p=1.00 | 0 | 97 | 1 | Aliot, | | non cardiovascular death | no data | | Adverse events leading to treatment discontinuation | 0.23 [0.05 1.11] | p=1.00 | 0 | 97 | 1 | Aliot, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| flecainide vs quinidine | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death or hospitalization for cardiac causes | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Atrial fibrillation recurrence | 1.04 [0.57 1.92] | p=1.00 | 0 | 239 | 1 | Naccarelli, | | Cardiac nonarrhythmic death | no data | | Cardiac arrhythmic death | no data | | Vascular noncardiac death | no data | | hospitalization for AF | no data | | hospitalisation for heart failure | no data | | Pro-arrhythmia | 1.49 [0.55 4.05] | p=1.00 | 0 | 239 | 1 | Naccarelli, | | All cause death | 1.04 [0.02 52.99] | p=1.00 | 0 | 239 | 1 | Naccarelli, | | non cardiovascular death | no data | | Adverse events leading to treatment discontinuation | 1.66 [0.90 3.05] | p=1.00 | 0 | 239 | 1 | Naccarelli, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
